PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2025

Table 1: Molecular Subtypes of Breast Cancer

Table 2: AJCC Stage Definitions for Breast Cancer

Table 3: Prognosis for Breast Cancer

Table 4: Risk Factors and Comorbidities for Breast Cancer

Table 5: 8MM, Most Recent Five-Year Relative Survival for Invasive Breast Cancer, Women (%)

Table 6: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Non-Invasive DCIS Breast Cancer

Table 7: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status

Table 8: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Invasive Breast Cancer

Table 9: 8MM, Sources of Epidemiological Data Used to Forecast Invasive Breast Cancer by HER2 Status

Table 10: 8MM, Sources of Epidemiological Data Used to Forecast the Relative Survival of Invasive Breast Cancer

Table 11: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Stage at Diagnosis

Table 12: 8MM, Sources of Epidemiological Data Used to Forecast HER2-, HR+ Invasive Breast Cancer by Stage at Diagnosis

Table 13: 8MM, Sources of Epidemiological Data Used to Forecast TN Invasive Breast Cancer by Stage at Diagnosis

Table 14: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Menopausal Status

Table 15: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Site of Metastasis

Table 16: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Type of Biomarker Expression

Table 17: 8MM, Sources Not Used in Epidemiological Analysis of Breast Cancer

Table 18: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015–2025

Table 19: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages =18 Years, N, 2015

Table 20: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015–2025

Table 21: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N (Row %), 2015

Table 22: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015–2025

Table 23: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, N, 2015

Table 24: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status, Women, Ages =18 Years, N, 2015

Table 25: Treatment Guidelines for HER2- Breast Cancer

Table 26: Most Prescribed Regimens for HER2- Breast Cancer by Drug Class in the Global Markets, 2015

Table 27: Country Profile – US

Table 28: Country Profile – France

Table 29: Country Profile – Germany

Table 30: Country Profile – Italy

Table 31: Country Profile – Spain

Table 32: Country Profile – UK

Table 33: Country Profile – Japan

Table 34: Country Profile – China

Table 35: Product Profile – Ibrance

Table 36: Summary of the Results of the PALOMA-2 Trial

Table 37: Summary of the Results of the PALOMA-3 Trial

Table 38: Safety profile of Ibrance + letrozole

Table 39: Safety Profile of Ibrance in Combination with Faslodex

Table 40: Ibrance SWOT Analysis, 2016

Table 41: Product Profile – Abraxane

Table 42: Efficacy of Abraxane

Table 43: Safety Profile of Abraxane

Table 44: Abraxane SWOT Analysis, 2016

Table 45: Product Profile – Afinitor (everolimus)

Table 46: Efficacy of Afinitor in Second-Line HER2-/HR+ Advanced Breast Cancer

Table 47: Safety Profile of Afinitor

Table 48: Afinitor SWOT Analysis, 2016

Table 49: Product Profile – Avastin

Table 50: Efficacy of Avastin in First Line Metastatic Breast Cancer

Table 51: Safety of Avastin in First-Line Metastatic Breast Cancer

Table 52: Avastin SWOT Analysis, 2016

Table 53: Product Profile – Halaven

Table 54: Efficacy of Halaven

Table 55: Safety Profile of Halaven

Table 56: Halaven SWOT Analysis, 2016

Table 57: Product Profile – Ixempra

Table 58: Efficacy of Ixempra Monotherapy

Table 59: Efficacy of Ixempra in Combination with Xeloda

Table 60: Safety Profile of Ixempra

Table 61: Ixempra SWOT Analysis, 2016

Table 62: Product Profile – Faslodex

Table 63: Efficacy of Faslodex in the First Line

Table 64: Efficacy of Faslodex Monotherapy in the Second Line

Table 65: Efficacy of Faslodex in the First Line

Table 66: Safety of Faslodex in the First Line

Table 67: Safety of Faslodex in the Second Line

Table 68: Faslodex SWOT Analysis, 2016

Table 69: Product Profile – Doxil

Table 70: Doxil SWOT Analysis, 2016

Table 71: Product Profile – Nolvadex/Soltamox

Table 72: AI Approvals in the 8MM

Table 73: Unmet Need and Opportunity in HER2- Breast Cancer

Table 74: Product Profile – Abemaciclib (LY2835219)

Table 75: Efficacy of Abemaciclib in Monotherapy in Pretreated HER2-/HR+ Metastatic Breast Cancer Patients (MONARCH 1 NCT02102490)

Table 76: Safety of Abemaciclib in Monotherapy in Pretreated HER2-/HR+ Metastatic Breast Cancer Patients

Table 77: Abemaciclib SWOT Analysis, 2016

Table 78: Product Profile – Ribociclib

Table 79: Efficacy of Ribociclib in Combination with Letrozole in HER2-/HR+ Metastatic Breast Cancer Patients (MONALEESA 2, NCT01958021)

Table 80: Most Common AEs of Ribociclib in Combination with Letrozole in HER2-/HR+ Metastatic Breast Cancer Patients (MONALEESA 2, NCT01958021)

Table 81: Ribociclib SWOT Analysis, 2015

Table 82: Product Profile – Lynparza

Table 83: Summary of the Results of the ICEBERG 1 Phase II Trial (NCT00494234)

Table 84: Summary of the Most Commonly Reported AEs, Occurring in at Least 20% of Patients With Advanced Ovarian Cancers Treated with Lynparza Monotherapy

Table 85: Lynparza SWOT Analysis, 2016

Table 86: Product Profile – Talazoparib

Table 87: Summary of the Most Commonly Reported AEs in Patients Treated with Talazoparib Monotherapy

Table 88: Talazoparib SWOT Analysis, 2016

Table 89: Product Profile – Veliparib

Table 90: Veliparib SWOT Analysis, 2016

Table 91: Product Profile – Niraparib

Table 92: Summary of the Main Reported AEs in Ovarian Cancer Patients Treated with Niraparib

Table 93: Niraparib SWOT Analysis 2016

Table 94: Product Profile – Buparlisib (BKM-120)

Table 95: Summary of the Results of the Trial of Buparlisib + Faslodex vs. Faslodex

Table 96: Summary of AEs From the Trial of Buparlisib + Faslodex vs. Faslodex

Table 97: Buparlisib SWOT Analysis

Table 98: Product Profile – Alpelisib (BYL- 719)

Table 99: Summary of the Results of the Alpelisib Trial

Table 100: Summary of AEs from the Trial of Alpelisib

Table 101: Alpelisib SWOT Analysis

Table 102: Product Profile – Taselisib (GDC-0032)

Table 103: Summary of the Results of the Taselisib Trial

Table 104: Summary of the Safety of Taselisib

Table 105: Taselisib SWOT Analysis

Table 106: Product Profile – Tecentriq

Table 107: Summary of the Results of the Phase Ib Trial of Tecentriq in Combination with Abraxane in Patients with mTNBC (Genetech, NCT01633970)

Table 108: Summary of AEs from the Phase Ib Trial of Tecentriq + Abraxane in Patients with mTNBC (Genetech, NCT01633970)

Table 109: Tecentriq SWOT Analysis, 2016

Table 110: Product Profile – Keytruda (Pembrolizumab)

Table 111: Summary of the Results of Keytruda in HER2-/HR+ Patients in the KEYNOTE-028 Trial (MSD, NCT02054806)

Table 112: Summary of AEs of All Grades for Keytruda in HER2-/HR+ Patients in the Keytruda KEYNOTE-028 Trial (MSD, NCT02054806)

Table 113: Summary of Grade 3-4 AEs from the Trial of Keytruda (MSD, NCT02054806)

Table 114: Keytruda SWOT Analysis, 2016

Table 115: Product Profile – Entinostat

Table 116: Efficacy Results from the ENCORE301 Trial of Exemestane + Entinostat vs. Exemestane + Placebo

Table 117: Most Commonly Reported AEs from the ENCORE301 trial of Exemestane + Entinostat vs. Exemestane + Placebo

Table 118: Entinostat SWOT, 2016

Table 119: Product Profile – Epidaza

Table 120: Most Commonly Reported AEs from the Phase II Trial of Epidaza + Exemestane

Table 121: Epidaza SWOT Analysis

Table 122: Product Profile – Sacituzumab Govitecan

Table 123: Summary of the Results of Sacituzimab Govitecan Phase I/II Trial in Metastatic TNBC (Immunomedics Inc., NCT01631552)

Table 124: Summary of AEs from the Phase I/II Trial of Sacituzimab Govitecan (Immunomedics Inc., NCT01631552)

Table 125: Sacituzimab Govitecan SWOT, 2016

Table 126: Product Profile – Glembatumumab vedotin

Table 127: Efficacy Results of the Phase IIb EMERGE Trial of Glembatumumab Vedotin Monotherapy in Metastatic TNBC (NCT01156753)

Table 128: Safety Results of the Phase IIb EMERGE Trial of Glembatumumab Vedotin Monotherapy in Solid Tumors

Table 129: Glembatumumab Vedotin SWOT, 2016

Table 130: Product Profile – Xtandi

Table 131: Summary of the Results of ENZA Phase II Xtandi Trial (NCT01889238)

Table 132: Summary of the Results of Xtandi Trial

Table 133: Xtandi SWOT Analysis, 2016

Table 134: Early Stage Clinical Development in HER2- Breast Cancer

Table 135: Key Companies in the Disease HER2- Breast Cancer Market in the 8MM, 2015

Table 136: Pfizer’s HER2- Metastatic Breast Cancer Portfolio Assessment, 2016

Table 137: Novartis’ HER2- Metastatic Breast Cancer Portfolio Assessment, 2016

Table 138: Roche’s HER2- Breast Cancer Portfolio Assessment, 2016

Table 139: AZ’s HER2- Breast Cancer Portfolio Assessment, 2016

Table 140: Global HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025

Table 141: Key Events Impacting Sales for HER2-/HR+ in the US, 2015–2025

Table 142: Key Events Impacting Sales for TNBC in the US, 2015–2025

Table 143: US HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025

Table 144: Key Events Impacting Sales for HER2-/HR+ Breast Cancer in the 5EU, 2015–2025

Table 145: Key Events Impacting Sales for TNBC in the 5EU, 2015–2025

Table 146: 5EU HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025

Table 147: Key Events Impacting Sales for HER2-/HR+ breast cancer in Japan, 2015–2025

Table 148: Key Events Impacting Sales for TNBC in Japan, 2015–2025

Table 149: Japanese HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025

Table 150: Key Events Impacting Sales for HER2-/HR+ Breast Cancer in China, 2015–2025

Table 151: Key Events Impacting Sales for TNBC in China, 2015–2025

Table 152: Chinese HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025

Table 153: Key Launch Dates in HER2- Breast Cancer

Table 154: Key Patent Expiries

Table 155: Average Body Weight and Surface Area Across the 8MM

Table 156: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country